Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adma Biologics Inc chart...

About the Company

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Exchange

NASDAQ

Website

admabiologics.com

$258M

Total Revenue

302

Employees

$2B

Market Capitalization

-68.38

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADMA News

A Closer Look at 6 Analyst Recommendations For ADMA Biologics

2d ago, source:

ADMA Biologics (NASDAQ:ADMA) has been analyzed by 6 analysts in the last three months, revealing a diverse range of ...

ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target

2d ago, source:

ADMA Biologics (ADMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...

ADMA Biologics Inc ADMA

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

ADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript

28d ago, source: Seeking Alpha

Good afternoon. And welcome to the ADMA Biologics Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Wednesday, February 28, 2024. At this time, all ...

ADMA Biologics Announces CFO Transition

29d ago, source: WATE 6 On Your Side

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company ...

ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29d ago, source: Finanznachrichten

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA (1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ...

ADMA Biologics Inc Reports Robust Revenue Growth and Positive Adjusted Net Income for FY 2023

29d ago, source: Yahoo Finance

Revenue Growth: ADMA Biologics Inc (NASDAQ:ADMA) reported a 68% increase in total revenues for FY 2023, reaching $258.2 million. Adjusted EBITDA: The company achieved $40.3 million in adjusted EBITDA ...

Q4 2023 ADMA Biologics Inc Earnings Call

28d ago, source: Yahoo Finance

Skyler Bloom; Senior Director, Corporate Strategy & Business Development; ADMA Biologics, Inc. Adam Grossman; Founder, Director, President & CEO; ADMA Biologics, Inc ...

ADMA Biologics Inc

15d ago, source: TheStreet.com

Below is a summary of the major fundamental and technical factors we consider when determining our overall recommendation of ADMA shares. It is provided in order to give you a deeper understanding ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript

28d ago, source: Yahoo Finance

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript February 28, 2024 ADMA Biologics, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $0.02.

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript

28d ago, source: Insider Monkey

ADMA Biologics, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $0.02. ADMA isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript

28d ago, source: Insider Monkey

It can only improve, Gary, and I don’t want to say, I want to stop making BIVIGAM, but look, ADMA Biologics founding principles were to make the products that nobody else wants to make.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...